晚期甲状腺癌的基因组特征与临床特征:日本全国数据库研究
该研究利用日本全国数据库回顾性观察552例需药物治疗的晚期甲状腺癌,分析基因变异与预后关系。结果显示62.7%存在可用药基因异常,TP53异常在分化型甲状腺癌中独立预测总生存更差(HR 2.205,95%CI 1.135-4.283),仑伐替尼治疗失败时间不因BRAF或RAS突变而不同。
要点
- 晚期甲状腺癌中62.7%存在可用药基因异常。
- TP53异常在分化型甲状腺癌中独立预测总生存更差(HR 2.205,95%CI 1.135-4.283)。
- 仑伐替尼治疗失败时间不因BRAF或RAS突变而不同。
核心结论
- 62.7%的晚期甲状腺癌存在可用药基因异常,TP53异常是分化型甲状腺癌总生存的独立不良预后因素。
- 仑伐替尼的治疗失败时间不因基因谱不同而不同。
研究设计与样本
- 日本全国数据库回顾性观察研究,数据库共53543例患者,其中纳入552例甲状腺癌。
主要发现
- 数据库包含未分化甲状腺癌23.6%、低分化甲状腺癌10.0%、分化型甲状腺癌66.4%。
- 最常见基因异常为TERT启动子66.3%、BRAF 56.7%、TP53 32.2%。
- 典型驱动基因为BRAF V600E 55.0%、RAS 18.5%、RET融合4.7%、NTRK融合1.6%、ALK融合0.4%。
- 在分化型甲状腺癌和低分化甲状腺癌中,TP53异常独立预测总生存更差(风险比=2.205,95%置信区间:1.135-4.283)。
- 在未分化甲状腺癌中,无基因异常与总生存相关。
关键数值与推荐
- 最常见治疗方案为仑伐替尼,尽管存在BRAF或RAS突变,治疗失败时间无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The relationship between the genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported. OBJECTIVE: To evaluate the treatment period and overall survival time for each genetic alteration in advanced thyroid carcinoma that requires drug therapy. METHODS: We conducted a retrospective observational study using a national database in Japan, which included 552 cases of thyroid carcinoma out of 53 543 patients in the database. RESULTS: The database included anaplastic thyroid carcinoma (23.6%), poorly differentiated thyroid carcinoma (10.0%), and differentiated thyroid carcinoma (66.4%). The most common genetic abnormalities were TERT promoter (66.3%), BRAF (56.7%), and TP53 (32.2%). The typical driver genes were BRAF V600E (55.0%), RAS (18.5%), RET fusion (4.7%), NTRK fusion (1.6%), and ALK fusion (0.4%). The most common regimen was lenvatinib, and the time to treatment failure was not different despite the presence of BRAF or RAS mutations. In differentiated thyroid carcinoma and poorly differentiated thyroid carcinoma, TP53 alterations independently predicted worse overall survival (hazard ratio = 2.205, 95% confidence interval: 1.135-4.283). In anaplastic thyroid carcinoma, no genetic alterations were associated with overall survival. CONCLUSION: Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
引用
- Toda S, Hiroshima Y, Iwasaki H, et al. Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan. J Clin Endocrinol Metab. 2024. PMID: 38630010. doi:10.1210/clinem/dgae271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。